Effects Of Benazepril Hydrochloride Tablets On Peritioneal Function And Residual Renal Function In Peritoneal Dialysis Patients

Objective To observe the angiotensin converting enzyme inhibitor (ACEI) BenazeprilHydrochloride Tablets on peritioneal function and whether the ACEI can protectresidual renal function in peritoneal dialysis patients, initially investigate peritonealfunction and residual renal function protective effect and possible mechanisms ofbenazepril.Methods Fifty ESRD patients undergoing regular continuous ambulatory peritonealdialysis (CAPD) were randomly assigned to Benazepril Hydrochloride Tablets (10mg/d,n=25) and control group (n=25). The observation period is12months. All patientsperformed peritioneal equilibration tests (PET) at the beginning and end of the study. Inall patients the e-GFR and24h urinary volume and daily ultrafiltration volume weredetected before and after the experiment. The Kt/V was tested after12months. Theexpression of transforming growth factor-βl (TGF-βl) in the overnight effluent wereexamined by enzyme-linked immunosorbent assay(ELISA) before and after theexperiment．Results1. At the beginning of study, no difference was found in residual renal functionbetween Benazepril Hydrochloride Tablets group and control group (P>0.05).12months later, the residual renal function decreased in both groups, but it reducedmore in the control group, the RRF of the Benazepril group was (1.87±0.63)ml/min and the control group was (1.11±0.46)ml/min, the difference wasstatistically significant (P<0.01).2. After12months, the24h urinary volume of the two group patients was initiallydecreased, and the control groups were decreased significantly compared with the benazepril group, the difference was statistically significant (P<0.01), while therewas no difference between the two groups daily urine volume at the beginning ofstudy.3. There was no significant difference between the PET and daily ultrafiltrationvolume of the two groups before the study, after12months, the PET of the twogroups were increased, and the control groups increased obviously, the differencewas statistically significant (P<0.05). The daily ultrafiltration volume of the controlgroup was decreased more significantly (P<0.05).4.12months later, the Kt/V of the Benazepril Hydrochloride group was1.77±0.09,and the control group1.59±0.09, the difference was statistically significant(P<0.01).5. At the end of the study, the transforming growth factor-βl in the overnightperitoneal dialysis increased more significantly in the control group compared withthe Benazepril Hydrochloride group (P<0.01), but no significant difference betweenthe two groups at the beginning.Conclusion Benazepril Hydrochloride Tablets may effectively protect the peritonealfunction, and its possible mechanism is inhibit the excessive expression ofprofibrogenic cytokines such as TGF-βl. The benazepril may reduce the rate of declineof residual renal function in patients with regular peritoneal dialysis.